Using Patient Preference to Inform Ritlecitinib Dose Selection for Alopecia Areata Treatment

January 2025 in “ The Journal of Dermatology ”

Brett Hauber, Chiara Whichello, Jonathan Mauer, Ernest H. Law, Myrto Trapali, Edward Whalen, Dalia Wajsbrot, Nicolas Krucien, Tommi Tervonen, Samuel H. Zwillich, Robert Wołk

ritlecitinib alopecia areata scalp hair loss hair regrowth eyebrows eyelashes

Studysummary This study found that patients with severe alopecia areata are willing to accept increased risks of serious infection, cancer, and blood clots when opting for a higher dose of ritlecitinib, valuing the potential for greater hair regrowth efficacy compared to a lower dose.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on onlinelibrary.wiley.com →

Discuss this study in the Community →

Research cited in this study

7 / 7 results

Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

January 2024 in “American journal of clinical dermatology”

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

research Treatment Preferences of Adults and Adolescents with Alopecia Areata: A Discrete Choice Experiment

December 2023 in “Journal of dermatology”

This study found that adult and adolescent patients with alopecia areata in the US and Europe are willing to accept significant risks of serious side effects, such as infection and cancer, to achieve effective hair regrowth with Janus kinase inhibitors.

research Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial

227 citations , April 2023 in “The Lancet”

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

research Two Phase 3 Trials of Baricitinib for Alopecia Areata

148 citations , March 2022 in “The New England Journal of Medicine”

In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.

research Evaluation of Stigma Toward Individuals With Alopecia

38 citations , March 2021 in “JAMA Dermatology”

This cross-sectional survey study found that stigmatizing attitudes toward people with alopecia are present in various social and professional settings, with stigma levels varying by alopecia severity and perceptions of its medical nature.

research JAK Inhibitors and Alopecia Areata

56 citations , January 2019 in “Lancet”

This review discusses the emerging use of JAK inhibitors in alopecia areata treatment and reports no new clinical results; it highlights hair regrowth despite symptom recurrence after stopping therapy.

research The Autoimmune Basis of Alopecia Areata: A Comprehensive Review

162 citations , October 2014 in “Autoimmunity reviews”

This review discusses alopecia areata, highlighting its autoimmune aspects, environmental triggers, and current treatment options, but reports no new clinical results; recent studies suggest JAK pathway intervention may offer therapeutic potential.